Venture(US:VEMLY) 2 1 Shi Ji Jing Ji Bao Dao·2025-12-18 23:15Core Viewpoint - Kolonbo Tai has reached a settlement agreement with Yilian Bio and its key personnel to resolve previous disputes, aiming to save litigation time and costs [1] Group 1: Settlement Agreement - The settlement involves Yilian Bio sharing revenue and net profits from six products (YL201, YL202, YL211, YL212, YL221, YL222) with Kolonbo Tai [1] - Kolonbo Tai stated that the settlement aligns with the overall interests of the company and its shareholders, and will not significantly impact the group's financial status or operations [1] Group 2: Background of the Dispute - The dispute originated from Kolonbo Tai's criminal complaint against Yilian Bio in 2024 and subsequent civil lawsuits in 2025 regarding alleged commercial secret infringements [1][2] - Key executives of Yilian Bio, including its founder and CEO, have previous ties to Kolonbo Tai, which may have contributed to the disputes [2][3] Group 3: Product Development and Collaborations - Yilian Bio's product YL201 is in Phase III clinical trials and received breakthrough therapy designation from the FDA for small cell lung cancer [6] - The company has established significant collaborations, including a global partnership with Roche for YL211, which includes a $50 million upfront payment and potential milestone payments nearing $1 billion [6][7] - Yilian Bio has also engaged in multiple strategic collaborations with BioNTech and Zai Lab, indicating strong business development activity [7] Group 4: Market Context and Future Prospects - The rapid resolution of the dispute may be linked to Yilian Bio's plans for an IPO, as resolving intellectual property issues is crucial for the approval process [2][8] - The current hot market for Hong Kong IPOs suggests that Yilian Bio could aim for a 2026 listing, emphasizing the importance of business development capabilities and clinical progress [8]